SLNO Soleno Therapeutics
- 42.4100
- -2.6100-5.80%
- 42.4100
- 0.00000.00%
Soleno Therapeutics News
Express News | Soleno Therapeutics Inc - Set to Join Russell 3000 Index
Soleno Therapeutics Set to Join Russell 3000 Index
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
NVIDIA has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking.
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $59
Stifel analyst Dae Gon Ha maintains $Soleno Therapeutics(SLNO.US)$ with a buy rating, and maintains the target price at $59.According to TipRanks data, the analyst has a success rate of 36.2% and a to
Piper Sandler Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $93
Piper Sandler analyst Yasmeen Rahimi maintains $Soleno Therapeutics(SLNO.US)$ with a buy rating, and maintains the target price at $93.According to TipRanks data, the analyst has a success rate of 35.
Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Soleno Therapeutics (SLNO)
Soleno Therapeutics Announces Oral Presentation Featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
Soleno Therapeutics, Inc. (NASDAQ: SLNO) today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4, 2024 in Boston, Massachusetts.
Soleno Therapeutics to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
Soleno Therapeutics Stands With the Prader-Willi Syndrome Community
This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome communityREDWOOD CITY, Calif., May 15, 2024 (GLOBE N
Soleno Therapeutics Is Maintained at Outperform by Oppenheimer
Soleno Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Soleno Therapeutics : Oppenheimer Cuts Target Price to $59 From $65
Soleno Therapeutics (SLNO) Receives a Buy From Stifel Nicolaus
Express News | Soleno Therapeutics Inc : Stifel Cuts Target Price to $59 From $63
Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target
Soleno Therapeutics (SLNO) has an average rating of buy and price targets ranging from $59 to $93, according to analysts polled by Capital IQ.
Express News | Soleno Therapeutics Inc : Guggenheim Raises Target Price to $61 From $51
Soleno Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 50.22% Baird → $72 Initiates Coverage On → Outperform 02/05/2024 94.03% Piper Sandler → $93 Ini
Express News | Soleno Therapeutics Inc : Baird Initiates Coverage With Outperform Rating; Target Price $72
Express News | Soleno Therapeutics Q1 2024 Adj EPS $(0.59) Misses $(0.37) Estimate
Soleno Therapeutics | 10-Q: Quarterly report
Soleno Therapeutics' DCCR Poised for FDA Approval and Blockbuster Sales: An Analyst's Bullish Outlook
Analysis
Price Target
No Data
